UAB Researchers Discover why Brain Neurons in Parkinson's Disease Stop Benefiting from Levodopa
The mechanism may be therapeutic target to prevent or reverse dyskinesia
Though the drug levodopa (L-DOPA) can dramatically improve Parkinson’s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition – involuntary repetitive, rapid and jerky movements. This abnormal motor behavior appears only while taking L-DOPA, a it stops if the drug is stopped. However, if L-DOPA is taken again, even many months later, it quickly re-emerges. In research to prevent this side effect and extend the usefulness of L-DOPA – which is the most effective drug treatment for Parkinson’s disease – University of Alabama at Birmingham researchers have uncovered an essential mechanism of this long-term memory for L-DOPA-induced-dyskinesia, or LID. To read more, click here.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2017
Oct. 26-28, 2017; Jacksonville, Fla.
Pituitary Tumors: Diagnostic and Treatment Dilemmas
Oct. 27, 2017; New York
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
8th World Congress of Neuroendoscopy
Nov. 1-4, 2017; Cape Town, South Africa
3rd Annual Selected Topics in Craniomaxillofacial Surgery
Nov. 4, 2017 - Nov. 5, 2017; Boston, Mass.